Microvast Holdings announces departure of chief financial officer
PLEASANTON, Calif. - In a significant development in the biotechnology patent landscape, 10x Genomics Inc. (NASDAQ:TXG), currently valued at $1.2 billion, has successfully obtained a worldwide permanent injunction against competitor Parse Biosciences. The injunction, which was agreed upon on February 25, 2025, prohibits Parse Biosciences from manufacturing, using, selling, or offering to sell its planned ATAC and ATAC-Multiome Single Cell products. According to InvestingPro data, 10x Genomics maintains a strong financial position with a current ratio of nearly 5x, indicating robust short-term liquidity.
The consent agreement, entered in the United States District Court for the District of Delaware, comes as a result of Parse Biosciences admitting that 10x Genomics’ patents related to ATAC-seq methods and compositions are valid, enforceable, and were infringed upon by their activities. This admission and the subsequent injunction occurred one week before the scheduled trial date. Despite this legal victory, InvestingPro analysis reveals the company faces significant market challenges, with its stock down over 76% in the past year. InvestingPro subscribers have access to 10+ additional key insights about TXG’s financial health and market position.
Eric S. Whitaker, Chief Legal Officer of 10x Genomics, commented on the resolution, stating, "This development further validates the strength of our broad patent portfolio, which helps protect and preserve the world-class innovation engine at 10x." He expressed satisfaction with the outcome and noted that the company’s litigation against Parse’s gene expression products is still ongoing, with additional patents under appeal.
Following the entry of the injunction, the trial set for March 2025 concerning 10x Genomics’ remaining patent infringement claims against Parse has been stayed pending the outcome of these appeals.
10x Genomics is a leader in the field of single-cell and spatial biology, providing tools and technologies that enable researchers to study biological systems with high resolution and scale. The company continues to defend its intellectual property rights vigorously and invests in innovative technologies that empower researchers globally.
The information in this article is based on a press release statement issued by 10x Genomics. The company’s forward-looking statements are subject to various risks and uncertainties, and there can be no assurance that the expectations reflected in these statements will be realized. The forward-looking statements should not be relied upon as representing the company’s views beyond the date of the press release.
In other recent news, 10X Genomics reported its fourth-quarter 2024 earnings, revealing a revenue of $165 million, which surpassed analyst expectations of $153.44 million but marked a 10% decline year-over-year. The company faced challenges with an EPS of -$0.40, missing the forecasted -$0.31, highlighting ongoing profitability issues. Despite these setbacks, 10X Genomics launched several new products and anticipates a 0-3% revenue growth for 2025, focusing on biopharma and single-cell projects. Analysts at Citi and Canaccord Genuity have both adjusted their price targets for the company, with Citi reducing it to $20 and Canaccord to $18, while maintaining a Buy rating. These adjustments reflect concerns over NIH funding uncertainties and the company’s commercial reorganization. The company is also transitioning to its Gen-X technology, which is expected to drive future growth, although pricing pressures may impact year-over-year revenues. 10X Genomics has set its fiscal year 2025 revenue guidance between $610-630 million, slightly below the consensus estimate. Despite the challenges, analysts remain optimistic about the company’s potential for growth once current headwinds subside.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.